Second Genome is engaged in a number of strategic collaborations for the discovery and development of microbiome-modulating therapeutics. These partnerships help identify and develop product candidates that modulate microbe-microbe and microbe-host interactions across multiple disease areas.

Partnership with the Mayo Clinic to access world-class clinical expertise

Second Genome has an extensive partnership with the Mayo Clinic Center for Individualized Medicine to support the development of therapeutic products for multiple disease indications, starting with inflammatory bowel disease, metabolic disorders, and colorectal cancer. To learn more about this collaboration read our press release.

Scientific collaboration with Alimentary Pharmabiotic Centre (APC) Microbiome Institute at University College Cork (UCC), Ireland

The focus of our collaboration with the APC at UCC is to identify bacterial species and mechanisms that are driving IBD biology. This alliance between academia and industry allows both groups to benefit from the other’s expertise and exchange ideas to accelerate new discoveries. To learn more about this collaboration read our press release.